Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.03 | 0.00 | -0.28 |
| FCF Yield | -55.86% | -91.41% | -72.87% | 0.33% |
| EV / EBITDA | -2.26 | -0.32 | -0.97 | -2.95 |
| Quality | ||||
| ROIC | -37.94% | -64.90% | -61.69% | -39.61% |
| Gross Margin | 99.96% | 83.65% | -370.48% | -1,706.64% |
| Cash Conversion Ratio | 1.03 | 1.24 | 0.86 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 87.18% | 114.02% | 90.00% | 76.31% |
| Free Cash Flow Growth | 47.91% | 15.01% | -8,904.36% | 103.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.93 | 0.55 | 0.80 |
| Interest Coverage | -20.54 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,121.23 | -16.88 | 498.49 | 1,991.97 |